Krystal Biotech, Inc. (KRYS) DCF Valuation

Krystal Biotech, Inc. (KRYS) DCF Valuation
  • ✓ Totalmente Editável: Adapte-Se Às Suas Necessidades No Excel Ou Planilhas
  • ✓ Design Profissional: Modelos Confiáveis ​​E Padrão Da Indústria
  • ✓ Pré-Construídos Para Uso Rápido E Eficiente
  • ✓ Não É Necessária Experiência; Fácil De Seguir

Krystal Biotech, Inc. (KRYS) Bundle

DCF model
Get Full Bundle:
$25 $15
$12 $7
$12 $7
$12 $7
$12 $7
$12 $7
$12 $7
$12 $7
$12 $7

TOTAL:

Explore the financial outlook of Krystal Biotech, Inc. (KRYS) with our user-friendly DCF Calculator! Enter your projections for growth, margins, and expenses to calculate the intrinsic value of Krystal Biotech, Inc. (KRYS) and enhance your investment strategy.


Discounted Cash Flow (DCF) - (USD MM)

Year AY1
2019		 AY2
2020		 AY3
2021		 AY4
2022		 AY5
2023		 FY1
2024		 FY2
2025		 FY3
2026		 FY4
2027		 FY5
2028
Revenue .0 .0 .0 .0 50.7 50.7 50.7 50.7 50.7 50.7
Revenue Growth, % 0 0 0 0 0 0 0 0 0 0
EBITDA -18.1 -30.3 -65.3 -145.2 17.9 44.1 44.1 44.1 44.1 44.1
EBITDA, % 100 100 100 100 35.31 87.06 87.06 87.06 87.06 87.06
Depreciation 1.0 1.9 2.8 4.1 5.0 41.6 41.6 41.6 41.6 41.6
Depreciation, % 100 100 100 100 9.88 81.98 81.98 81.98 81.98 81.98
EBIT -19.1 -32.2 -68.1 -149.3 12.9 43.1 43.1 43.1 43.1 43.1
EBIT, % 100 100 100 100 25.44 85.09 85.09 85.09 85.09 85.09
Total Cash 193.7 271.3 438.1 379.2 532.2 50.7 50.7 50.7 50.7 50.7
Total Cash, percent .0 .0 .0 .0 .0 .0 .0 .0 .0 .0
Account Receivables .0 .0 .0 .0 42.0
Account Receivables, % 100 100 100 100 82.92
Inventories .0 .0 .0 .0 7.0 42.0 42.0 42.0 42.0 42.0
Inventories, % 100 100 100 100 13.78 82.76 82.76 82.76 82.76 82.76
Accounts Payable .7 2.1 8.4 4.0 1.8 40.9 40.9 40.9 40.9 40.9
Accounts Payable, % 100 100 100 100 3.65 80.73 80.73 80.73 80.73 80.73
Capital Expenditure -6.4 -14.8 -68.3 -53.0 -11.8 -2.4 -2.4 -2.4 -2.4 -2.4
Capital Expenditure, % 100 100 100 100 -23.27 -4.65 -4.65 -4.65 -4.65 -4.65
Tax Rate, % 15.24 15.24 15.24 15.24 15.24 15.24 15.24 15.24 15.24 15.24
EBITAT -19.1 -32.2 -68.1 -149.3 10.9 41.8 41.8 41.8 41.8 41.8
Depreciation
Changes in Account Receivables
Changes in Inventories
Changes in Accounts Payable
Capital Expenditure
UFCF -23.8 -43.8 -127.4 -202.6 -47.0 78.2 81.0 81.0 81.0 81.0
WACC, % 8.31 8.31 8.31 8.31 8.31 8.31 8.31 8.31 8.31 8.31
PV UFCF
SUM PV UFCF 318.3
Long Term Growth Rate, % 2.00
Free cash flow (T + 1) 83
Terminal Value 1,309
Present Terminal Value 878
Enterprise Value 1,196
Net Debt -350
Equity Value 1,547
Diluted Shares Outstanding, MM 28
Equity Value Per Share 55.73

What You Will Get

  • Real Krystal Biotech Data: Preloaded financials – from revenue to EBIT – based on actual and projected figures for Krystal Biotech, Inc. (KRYS).
  • Full Customization: Adjust all critical parameters (yellow cells) like WACC, growth %, and tax rates specific to Krystal Biotech.
  • Instant Valuation Updates: Automatic recalculations to analyze the impact of changes on Krystal Biotech’s fair value.
  • Versatile Excel Template: Tailored for quick edits, scenario testing, and detailed projections for Krystal Biotech, Inc. (KRYS).
  • Time-Saving and Accurate: Skip building models from scratch while maintaining precision and flexibility for Krystal Biotech.

Key Features

  • Customizable Growth Metrics: Adjust vital inputs such as revenue projections, R&D spending, and operational costs.
  • Instant DCF Valuation: Quickly computes intrinsic value, NPV, and additional financial metrics.
  • High-Precision Results: Leverages Krystal Biotech's actual financial data for accurate valuation insights.
  • Effortless Scenario Analysis: Easily explore various assumptions and evaluate their impact on results.
  • Efficiency Booster: Remove the hassle of constructing intricate valuation models from the ground up.

How It Works

  1. Step 1: Download the Excel file.
  2. Step 2: Review pre-entered Krystal Biotech data (historical and projected).
  3. Step 3: Adjust key assumptions (yellow cells) based on your analysis.
  4. Step 4: View automatic recalculations for Krystal Biotech’s intrinsic value.
  5. Step 5: Use the outputs for investment decisions or reporting.

Why Choose This Calculator for Krystal Biotech, Inc. (KRYS)?

  • Accuracy: Utilizes real Krystal Biotech financial data for precise calculations.
  • Flexibility: Allows users to easily test and adjust inputs as needed.
  • Time-Saving: Eliminate the need to create a DCF model from the ground up.
  • Professional-Grade: Crafted with the precision and usability expected at the CFO level.
  • User-Friendly: Designed for ease of use, suitable for those without extensive financial modeling skills.

Who Should Use Krystal Biotech, Inc. (KRYS)?

  • Investors: Gain insights into innovative therapies with a reliable valuation tool.
  • Financial Analysts: Streamline your analysis process with a customizable DCF model tailored for biotech.
  • Consultants: Effortlessly modify the template for client reports or presentations in the biotech sector.
  • Biotech Enthusiasts: Enhance your knowledge of biotech valuation methods through practical examples.
  • Educators and Students: Utilize it as a hands-on resource for finance and biotech courses.

What the Template Contains

  • Operating and Balance Sheet Data: Pre-filled Krystal Biotech historical data and forecasts, including revenue, EBITDA, EBIT, and capital expenditures.
  • WACC Calculation: A dedicated sheet for Weighted Average Cost of Capital (WACC), including parameters like Beta, risk-free rate, and share price.
  • DCF Valuation (Unlevered and Levered): Editable Discounted Cash Flow models showing intrinsic value with detailed calculations.
  • Financial Statements: Pre-loaded financial statements (annual and quarterly) to support analysis.
  • Key Ratios: Includes profitability, leverage, and efficiency ratios for Krystal Biotech, Inc. (KRYS).
  • Dashboard and Charts: Visual summary of valuation outputs and assumptions to analyze results easily.

No products were found matching.